Cisplatin or cetuximab with conventional versus redistributed radiotherapy for advanced head and neck cancer

Phase 2, randomised, open-label trial of cetuximab and cisplatin in head and neck squamous cell carcinoma (HNSCC), oropharyngeal cancer, mouth cancer and 1 more (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Locoregional recurrence-free survival at 2 years and Correlation of anatomical distribution of zirconium-89 cetuximab uptake with treatment arm and recurrence location. Planned start May 2011; status: withdrawn.